Skip to main navigation
Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact

Investor Relations

  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Committee Composition

Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Samuel Broder, MD Nominating and Corporate Governance Committee
Bob Holmen Audit Committee Compensation Committee
James Peyer, PhD Audit Committee Nominating and Corporate Governance Committee
Thomas Ricks Audit Committee Compensation Committee
Deneen Vojta, MD Nominating and Corporate Governance Committee
= Chairperson = Member

Investor Tools

  • Email Alerts
  • Investor FAQs
  • RSS Feeds
  • Contact Us
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone-icon

+1.240.243.8000

 

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
email-icon

info@senseibio.com

 

© 2021 Sensei Biotherapeutics, Inc. All Rights Reserved.

Legal

  • Privacy Policy

Social Links

Go to Top